Long-term outcome of patients receiving haematopoietic allogeneic stem cell transplantation as first transplant for high-risk Hodgkin lymphoma: a retrospective analysis from the Lymphoma Working Party-EBMT
Authors
Gutiérrez-García, G.Martínez, C.
Boumendil, A.
Finel, H.
Malladi, R.
Afanasyev, B.
Tsoulkani, A.
Wilson, K. M. O.
Bloor, Adrian
Nikoloudis, M.
Richardson, D.
López-Corral, L.
Castagna, L.
Cornelissen, J.
Giltat, A.
Collin, M.
Fanin, R.
Bonifazi, F.
Robinson, S.
Montoto, S.
Peggs, K. S.
Sureda, A.
Affiliation
Department of Haematology, Bone Marrow Transplantation Unit, Hospital Clinic of Barcelona, University of Barcelona, Institut de Recerca Biomèdica August Pi i Sunyer, Barcelona, SpainIssue Date
2021
Metadata
Show full item recordAbstract
We analysed long-term outcome of patients receiving haematopoietic allogeneic stem cell transplantation (allo-HSCT) as a first transplant for high-risk Hodgkin lymphoma (HL). One hundred and ninety patients were included in this study, 63% of them had previously received brentuximab vedotin and/or checkpoint inhibitors. Seventy patients (37%) received an unrelated donor allo-HSCT, 99 (51%) had myeloablative conditioning (MAC) and 60% had in vivo T-cell/depleted grafts (TCD). The 100-day cumulative incidence (CI) of grade II-IV acute graft-versus-host disease (GVHD) was 25% and the 3-year CI of chronic GVHD was 38%. The 3-year CI of non-relapse mortality (NRM) and relapse rate were 21% and 38% respectively. After a median follow-up of 58 months, 3-year overall survival (OS) and progression-free survival (PFS) were 58% and 41% respectively. Multivariate analysis showed that, in comparison to reduced-intensity conditioning regimens with or without TCD, MAC using TCD had similar NRM and a lower risk of relapse leading to significantly better OS and PFS. MAC without TCD was associated with higher NRM and worse survival outcomes. These results suggest that in patients with high-risk HL and candidates of allo-HSCT, a MAC strategy with TCD might be the best option.Citation
Gutiérrez‐García G, Martínez C, Boumendil A, Finel H, Malladi R, Afanasyev B, et al. Long‐term outcome of patients receiving haematopoietic allogeneic stem cell transplantation as first transplant for high‐risk Hodgkin lymphoma: a retrospective analysis from the Lymphoma Working Party‐EBMT [Internet]. British Journal of Haematology. Wiley; 2021.Journal
British Journal of HaematologyDOI
10.1111/bjh.17939PubMed ID
34750806Additional Links
https://dx.doi.org/10.1111/bjh.17939Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1111/bjh.17939
Scopus Count
Collections
Related articles
- Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
- Authors: Genadieva-Stavrik S, Boumendil A, Dreger P, Peggs K, Briones J, Corradini P, Bacigalupo A, Socié G, Bonifazi F, Finel H, Velardi A, Potter M, Bruno B, Castagna L, Malladi R, Russell N, Sureda A
- Issue date: 2016 Dec
- Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.
- Authors: Santoro N, Ruggeri A, Labopin M, Bacigalupo A, Ciceri F, Gülbaş Z, Huang H, Afanasyev B, Arcese W, Wu D, Koc Y, Tischer J, Santarone S, Giebel S, Mohty M, Nagler A
- Issue date: 2017 May 30
- Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
- Authors: Nagler A, Labopin M, Houhou M, Aljurf M, Mousavi A, Hamladji RM, Al Zahrani M, Bondarenko S, Arat M, Angelucci E, Koc Y, Gülbas Z, Sica S, Bourhis JH, Canaani J, Brissot E, Giebel S, Mohty M
- Issue date: 2021 Apr 1
- Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma.
- Authors: Ahmed S, Ghosh N, Ahn KW, Khanal M, Litovich C, Mussetti A, Chhabra S, Cairo M, Mei M, William B, Nathan S, Bejanyan N, Olsson RF, Dahi PB, van der Poel M, Steinberg A, Kanakry J, Cerny J, Farooq U, Seo S, Kharfan-Dabaja MA, Sureda A, Fenske TS, Hamadani M
- Issue date: 2020 Aug
- A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
- Authors: Gooptu M, Kim HT, Ho VT, Alyea EP, Koreth J, Armand P, Ritz J, Nikiforow S, Glotzbecker BE, Nageshwar P, Soiffer RJ, Antin JH, Cutler CS
- Issue date: 2018 Aug